There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SurModics (SRDX – Research Report), Urogen Pharma (URGN – Research Report) and Blueprint Medicines (BPMC – Research Report) with bullish sentiments.
SurModics (SRDX)
In a report released today, Brooks O’Neil from Lake Street maintained a Buy rating on SurModics, with a price target of $75.00. The company’s shares closed last Monday at $33.56.
According to TipRanks.com, O’Neil is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SurModics with a $63.33 average price target.
See today’s best-performing stocks on TipRanks >>
Urogen Pharma (URGN)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Urogen Pharma on January 18 and set a price target of $54.00. The company’s shares closed last Monday at $14.86.
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of
Urogen Pharma has an analyst consensus of Strong Buy, with a price target consensus of $43.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRDX:
